Abbott-Alere Deal Wins Conditional US Antitrust Approval

The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories' (ABT) acquisition of Alere (ALR).

Mastercard Beats Analyst Estimates for 2Q17, Net Income Rose 20%

Mastercard (MA) posted net income of $1.2 billion in 2Q17, reflecting a substantial increase of 20% from its 2Q16 net income.

How DOW’s Performance Materials and Chemicals Segment Performed

Dow Chemical's (DOW) Performance Materials and Chemicals (or PM&C) segment is the company's third-largest revenue generator, accounting for 18.5% of the company's revenue.

Anthem Was the S&P 500’s Top Loser on September 12

Anthem, a US health insurance company, was the S&P 500's top loser on September 12. Anthem fell 3.4% to $189.24—the biggest fall in ten months.

Merger must-knows: The shareholder vote and 90% tender condition

Once the SEC approves the proxy, a vote is scheduled. Usually, the last condition for a deal is the vote of the target shareholders.

How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16?

GlaxoSmithKline’s (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.

A Look at Abraxane’s Revenue Growth Trajectory in 2018

In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.

Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?

In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.

Boston Scientific: Focused on Category Leadership in Endoscopy

Boston Scientific (BSX) has estimated the market opportunity in pancreaticobiliary disease to be $1.4 billion in 2018 and $1.7 billion by 2021.